Paitoon Rashatasakhon | Fluorescent Dyes | Innovative Research Award

Published on by Cell Biologist

Innovative Research Award

Paitoon Rashatasakhon
Chulalongkorn University, Thailand

Paitoon Rashatasakhon
Affiliation Chulalongkorn University
Country Thailand
Scopus ID 6603258134
Documents 88
Citations 2,123
h-index 28
Subject Area Fluorescent Dyes
Event World Cell Biologist Awards
ORCID 0000-0002-7993-7968

Paitoon Rashatasakhon is a researcher affiliated with Chulalongkorn University, Thailand, whose scholarly profile includes research associated with fluorescent dyes and related areas of chemical and biological applications. The recognition presented here is associated with the Innovative Research Award under the World Cell Biologist Awards. Bibliographic indicators such as publication counts, citation counts and the h-index are commonly used to describe aspects of a researcher’s scholarly output and citation impact.  [1]

Abstract

Paitoon Rashatasakhon is affiliated with Chulalongkorn University in Thailand and is identified in the supplied research profile with a subject-area focus on fluorescent dyes. The profile records 88 documents, 2,123 citations and an h-index of 28. Fluorescent dyes constitute an important research domain because fluorescent molecules can provide sensitive optical signals for analytical chemistry, molecular recognition, imaging and biological investigation. [2] The Innovative Research Award recognizes research activity presented in the context of the World Cell Biologist Awards, with this profile emphasizing bibliographic output, citation impact and relevance to fluorescence-based research.

Keywords

Innovative Research Award; Paitoon Rashatasakhon; Chulalongkorn University; Fluorescent Dyes; Fluorescence Chemistry; Molecular Probes; Bioimaging; Research Impact

Introduction

Fluorescence-based methods occupy an important position across modern chemical and life-science research. Fluorescent dyes and probes can convert molecular interactions or environmental changes into measurable optical signals, supporting applications that range from chemical sensing to cellular and molecular imaging. [2] The development of fluorescent probes has also contributed to the investigation of biological processes where spatial and temporal information is important.

Research Profile

The supplied profile identifies Paitoon Rashatasakhon as a researcher at Chulalongkorn University, Thailand, with a research focus associated with fluorescent dyes. The stated Scopus record contains 88 documents, 2,123 citations and an h-index of 28. The corresponding Scopus author identifier is 6603258134. [1]

Research Contributions

Research involving fluorescent dyes may contribute to the development of molecules and analytical strategies capable of generating detectable optical responses. Depending on molecular design and application, fluorescent systems can be used to investigate chemical environments, molecular interactions and biological phenomena. [2] Fluorescent probes are also relevant to biological research because appropriately designed fluorophores can provide information about cellular structures, biochemical events and molecular targets. The field therefore intersects chemistry, analytical science, molecular biology and cell biology. [4]

Publications

The supplied profile reports 88 documents indexed in Scopus. [1] A complete publication bibliography should be retrieved directly from the researcher’s current institutional and bibliographic profiles because publication lists, citation counts and indexing records can change over time.

For scholarly evaluation, publications in fluorescent-dye research can encompass synthetic chemistry, photophysical characterization, sensing, molecular recognition, imaging and applications in biological systems. Fluorescent probes have been extensively studied for their ability to provide optical responses to specific chemical or biological conditions. [3]

Research Impact

The supplied bibliometric profile records 2,123 citations and an h-index of 28 across 88 documents. [1] These figures indicate measurable citation activity associated with the indexed publication record. Citation-based indicators are most appropriately considered alongside the quality, originality, relevance and reproducibility of the underlying research.[4]

Research on fluorescent systems may also support the development of probes with improved selectivity, sensitivity and photophysical characteristics. Such advances can be relevant to chemical sensing, molecular diagnostics and imaging-oriented research, depending on the intended application and validation of each system. [5]

Award Suitability

The Innovative Research Award profile is aligned with the supplied research information concerning Paitoon Rashatasakhon, particularly the stated subject area of fluorescent dyes and the documented bibliographic indicators. The relationship between fluorescent-dye chemistry and cell biology provides an interdisciplinary basis for considering research that contributes methods, probes or analytical approaches applicable to biological investigation.

Conclusion

Paitoon Rashatasakhon of Chulalongkorn University, Thailand, is presented in the supplied profile as a researcher working in the area of fluorescent dyes. The profile reports 88 documents, 2,123 citations and an h-index of 28. Fluorescent-dye research occupies an interdisciplinary position connecting chemical design, analytical measurement and biological investigation. [2]

References

  1. Elsevier. (n.d.). Scopus author details: Paitoon Rashatasakhon, Author ID 6603258134. Scopus.
    https://www.scopus.com/pages/authors/6603258134
  2. S Namuangruk, P Rashatasakhon., et al. (2020). Solvatochromic triazaborolopyridinium probes toward ultra-sensitive trace water detection in organic solvents.
    https://www.sciencedirect.com/science/article/pii/S0143720820304654
  3. M Sukwattanasinitt, P Rashatasakhon., et al. (2021). Fluorescent sensor for copper (II) and cyanide ions via the complexation–decomplexation mechanism with di (bissulfonamido) spirobifluorene.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC8246698/
  4. P Rashatasakhon, T Kumchoo, V Promarak, et al. (2010). Dipyrenylcarbazole Derivatives for Blue Organic Light‐Emitting Diodes.
    https://www.academia.edu/download/45727478/asia.20100030420160517-24947-14faydz.pdf
  5. P Chinapang, V Ruangpornvisuti, M Sukwattanasinitt, P Rashatasakhon. (2015). Ferrocenyl derivative of 1, 8-naphthalimide as a new turn-on fluorescent sensor for Au (III) ion.
    https://www.sciencedirect.com/science/article/pii/S0143720814002903

Amir Zarebkohan | Nanomedicine | Best Researcher Award

Published on by Cell Biologist

Dr. Amir Zarebkohan | Nanomedicine | Best Researcher Award

Tabriz University of Medical Sciences | Iran

Dr. Amir Zarebkohan’s research focuses on the development of advanced nanomedicine strategies for targeted drug delivery and cancer therapy. His work integrates medical nanotechnology and physiology to design innovative nanosystems capable of precise drug transport within biological environments. He specializes in smart targeted delivery platforms, nano–bio interface studies, and nano chemo-immunotherapy approaches aimed at improving therapeutic efficacy while minimizing systemic toxicity. His current projects involve the co-delivery of cyclophosphamide and HLH peptide using D8 and RIVAP-modified chitosan nanoparticles, engineered to respond to the redox conditions of the tumor microenvironment for glioma targeting in rat models. Additionally, he is developing chitosan-based nanoparticles containing dendrimers loaded with cyclophosphamide and sitagliptin, further functionalized with targeting ligands for enhanced delivery efficiency. His research emphasizes translational applications of nanotechnology in oncology and the exploration of biocompatible polymeric carriers for controlled and localized drug release. Through his studies, Dr. Zarebkohan contributes to advancing nano-chemoimmunotherapeutic platforms that bridge the gap between nanoscience and clinical medicine, offering potential breakthroughs in the treatment of complex and resistant cancers.

Profiles:  Google Scholar | Scopus | Orcid

Featured Publications:

Zarebkohan, A., & colleagues. (2024). Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model. Scientific Reports, 14, Article 75042.

Zarebkohan, A., & colleagues. (2024). Discovery of a novel dual targeting peptide for human glioma: From in-silico simulation to acting as targeting ligand. Advanced Pharmaceutical Bulletin, 14, Article 033.

Zarebkohan, A., & colleagues. (2023). Dual targeting salinomycin-loaded smart nano-micelles for enhanced accumulation and therapeutic outcome in breast cancer. International Journal of Pharmaceutics, 123095.

Zarebkohan, A., & colleagues. (2023). CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE model of mice. International Journal of Pharmaceutics, 122815.

Zarebkohan, A., & colleagues. (2023). Exosomal transmission of viruses, a two-edged biological sword. Cell Communication and Signalling, 21, Article 37.

Alessandra Luchini | Microbial Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Alessandra Luchini | Microbial Cell Biology | Best Researcher Award

Dr. Alessandra Luchini , George Mason University , United States

Dr. Alessandra Luchini is a renowned professor at George Mason University, VA, and director of the Ph.D. program in Biosciences at the School of Systems Biology. With expertise in proteomics, nanotechnology, and bioengineering, she is committed to advancing diagnostics and therapeutics for diseases such as cancer, infections, and inflammatory diseases. Dr. Luchini holds a Ph.D. in Bioengineering from the University of Padova, Italy, and has contributed significantly to scientific research, publishing peer-reviewed papers and co-inventing multiple patents in nanotechnology and proteomics. As a co-founder of Ceres Nanosciences Inc. and Monet Pharmaceuticals, her work bridges academia and industry. Dr. Luchini’s innovations have earned her recognition, including being named one of the “Top 10 Brilliant Scientists” by Popular Science in 2011 and receiving the Outstanding Faculty Award in 2023 from the State Council of Higher Education for Virginia.

Publication Profile:

Orcid

Strengths for the Award:

Dr. Alessandra Luchini has a distinguished career, marked by her leadership at George Mason University, where she is both a tenured professor and the director of the Ph.D. Biosciences program. She is a key innovator in the areas of proteomics, nanotechnology, and bioengineering, contributing significantly to advancements in diagnostics and therapeutics for cancer, infectious, and inflammatory diseases. Notable strengths include:

  • Innovative Research: Dr. Luchini has developed groundbreaking technologies such as highly accurate proteomic diagnostic assays, and she is involved in drug resistance research for medulloblastoma. Her work on Borrelia peptides and bacteriophage therapy shows her ability to address complex issues in medicine.
  • Collaboration and Impact: She is co-founder of successful companies, Ceres Nanosciences and Monet Pharmaceuticals, and has been recognized as one of the top 10 most brilliant scientists by Popular Science in 2011.
  • Extensive Publication Record: With an H-index of 31, Dr. Luchini has published numerous influential articles and is highly cited in her field. Her innovative research crosses multiple disciplines, from nanotechnology to clinical diagnostics.
  • Patent Portfolio: She holds several patents for advancements in biomarker harvesting, immunoassays, and hydrogel particles, demonstrating her ability to translate research into practical applications.

Areas for Improvement:

While Dr. Luchini’s research has immense impact in both academic and practical settings, a potential area for improvement could involve expanding her work into more personalized medicine approaches. While she is already exploring diagnostics for specific diseases like medulloblastoma, further integration of genomics and individualized treatment plans could enhance her future work. Additionally, broadening her interdisciplinary collaborations to include non-traditional fields like AI-based diagnostics could further elevate her contributions.

Education:

Dr. Alessandra Luchini’s educational journey began at the University of Padova in Italy, where she earned a Bachelor’s degree in Chemical Engineering with honors in 2001. She continued her academic path by pursuing a Ph.D. in Bioengineering, completing the program in 2005. Dr. Luchini further enhanced her expertise through postgraduate training in Proteomics and Nanotechnology at George Mason University in 2007. Her academic training laid the foundation for her pioneering research in nanotechnology and proteomics, areas in which she has significantly contributed to both scientific publications and patent innovations. Her multidisciplinary approach combines engineering, biotechnology, and molecular medicine, making her a leading expert in the development of cutting-edge diagnostic tools and therapeutic strategies. Dr. Luchini’s work is instrumental in bridging scientific theory with real-world applications in healthcare.

Experience:

Dr. Alessandra Luchini has held significant roles at George Mason University, where she has been a professor in the School of Systems Biology since June 2020. In addition to her academic position, she has served as the Graduate Program Director for the Ph.D. program in Biosciences since January 2019. Prior to her tenure at George Mason, Dr. Luchini was involved in both academic research and industry, co-founding Ceres Nanosciences Inc. in 2008 and Monet Pharmaceuticals in 2019. Her work at these companies and within academia revolves around developing advanced diagnostic tools and therapeutics for a wide range of diseases, including cancer and infectious diseases. Dr. Luchini has authored numerous publications in peer-reviewed journals and holds several patents in the fields of nanotechnology and proteomics. Her innovative approach to healthcare solutions, blending academic research with practical applications, has made her an influential figure in the scientific community.

Awards and Honors:

Dr. Alessandra Luchini has earned several prestigious awards throughout her career, highlighting her remarkable contributions to science and technology. In 2011, she was named one of Popular Science‘s “Top 10 Most Brilliant Scientists,” a recognition that speaks to her significant impact in nanotechnology and proteomics. In 2023, Dr. Luchini was awarded the State Council of Higher Education for Virginia’s Outstanding Faculty Award, which acknowledged her exceptional work in education and research. Her achievements also include co-founding two innovative companies—Ceres Nanosciences Inc. and Monet Pharmaceuticals—which have developed cutting-edge diagnostic tools. In addition to these accolades, Dr. Luchini has received multiple research grants and honors for her work in biosciences, reinforcing her position as a leading expert in proteomics and nanotechnology. Her numerous awards underscore her leadership and transformative influence in the fields of molecular medicine and biotechnology.

Research Focus:

Dr. Alessandra Luchini’s research focuses on developing novel technologies for diagnostics and therapeutics in cancer, infectious, and inflammatory diseases. A key area of her work is the application of proteomics and nanotechnology to improve the detection and treatment of these conditions. She aims to create highly accurate diagnostic assays, including point-of-care devices that can be used to identify active infections like borreliosis. Another significant part of her research is tackling drug resistance in cancers like medulloblastoma, where she investigates the interaction of BAG-containing protein complexes to identify potential therapeutic targets. Additionally, Dr. Luchini’s research spans the development of nanotechnology-based diagnostic systems, such as the use of smart hydrogel particles and nanoparticle-enhanced immunoassays. Her work has substantial real-world applications, bridging the gap between cutting-edge science and practical healthcare solutions, with the goal of improving patient outcomes across a range of diseases.

Publications Top Notes:

  1. Urinary bacteriophage cooperation with bacterial pathogens during human urinary tract infections supports lysogenic phage therapy 🔬🦠 (Commun Biol, 2025)
  2. Urinary Borrelia Peptides Correlate with the General Symptom Questionnaire (GSQ30) Scores in Symptomatic Patients with Suspicion of Tick-borne Illness 🦠💡 (J Cell Immunol, 2025)
  3. Hearing Science Accelerator: Sudden Sensorineural Hearing Loss-Executive Summary of Research Initiatives 🧠🔊 (Otol Neurotol, 2024)
  4. A set of diagnostic tests for detection of active Babesia duncani infection 🧬🦠 (Int J Infect Dis, 2024)
  5. Protein Painting Mass Spectrometry in the Discovery of Interaction Sites within the Acetylcholine Binding Protein 🔬💉 (ACS Chem Neurosci, 2024)
  6. Wheat-Based Glues in Conservation and Cultural Heritage: (Dis)solving the Proteome of Flour and Starch Pastes and Their Adhering Properties 🏛️🧬 (J Proteome Res, 2024)
  7. Identification of Unambiguous Borrelia Peptides in Human Urine Using Affinity Capture and Mass Spectrometry 🔬💧 (Methods Mol Biol, 2024)
  8. Molecular and functional profiling of chemotolerant cells unveils nucleoside metabolism-dependent vulnerabilities in medulloblastoma 🧠⚡ (Acta Neuropathol Commun, 2023)
  9. Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling 🧬💉 (J Biol Chem, 2023)
  10. Drug discovery efforts at George Mason University 💊🧠 (SLAS Discov, 2023)

Conclusion:

Dr. Alessandra Luchini is an exceptional candidate for the Best Researcher Award, given her remarkable achievements in advancing scientific knowledge, developing life-saving technologies, and establishing successful enterprises. Her innovative work continues to shape the future of diagnostics and therapeutics, making her highly deserving of such an honor.